Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5133
Peer-review started: March 17, 2021
First decision: July 3, 2021
Revised: July 31, 2021
Accepted: April 20, 2022
Article in press: April 20, 2022
Published online: June 6, 2022
Processing time: 441 Days and 14.7 Hours
Pandemics obligate providers to transform their clinical practice. An extensive effort has been put to find out feasible approaches for gastrointestinal diseases and also to manage coronavirus disease 2019 (COVID-19) related gastrointestinal conditions. Diarrhea, hepatitis, and pancreatitis can be seen in the COVID-19 course. Endoscopic procedures increase the risk of contamination for medical staff and patients despite precautions, therefore indications should be tailored to balance risks vs benefits. Furthermore, whether the immunosupression in inflammatory bowel diseases, liver transplantation, and autoimmune liver diseases increases COVID-19 related risks and how to modify immunosupression are topics of ongoing debate. This review aims to provide most up to date practical approaches that a gastrointestinal fellow should be aware on the problems and management of gastrointestinal and hepatobiliary diseases during the COVID-19 pandemic.
Core Tip: Along with the rise of new gastrointestinal and hepatopancreatic problems during the coronavirus disease 2019 (COVID-19) pandemic, patients and physicians involved in gastroenterology faced serious challenges in managing diseases.All these necessitated modifying our daily clinical practice in COVID-19 era. Here this review provides guidance for diarrhea, pancreatitis, hepatitis, inflammatory bowel disease, autoimmune hepatitis, liver transplantation, and endoscopic procedures based on most current evidence from the literature.